MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.61
-0.20
-1.41%
Opening 11:59 01/27 EST
OPEN
13.50
PREV CLOSE
13.80
HIGH
13.76
LOW
13.15
VOLUME
343.33K
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
10.26
MARKET CAP
664.98M
P/E (TTM)
-6.9290
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NTLA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NTLA News

  • These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
  • MotleyFool.com.01/18 14:00
  • European ruling threatens Broad's CRISPR gene-editing patents
  • American City Business Journals.01/17 19:09
  • Intellia Therapeutics highlights anticipated 2020 milestones
  • Seeking Alpha - Article.01/09 14:26
  • Intellia Therapeutics Highlights Expected 2020 Milestones
  • Benzinga.01/09 12:33

More

Industry

Biotechnology & Medical Research
-0.97%
Pharmaceuticals & Medical Research
-0.44%

Hot Stocks

Name
Price
%Change

About NTLA

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers Intellia Therapeutics Inc (NTLA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.